Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Stroke patients ...
In a meta-analysis presented at the European Stroke Organization Conference, alteplase was more effective than placebo for treatment of acute ischemic stroke between 4.5 and 9 hours after onset.
Recent use of direct oral anticoagulants (DOACs) does not seem to be associated with increased risk of intracranial hemorrhage among patients with acute ischemic stroke treated with intravenous ...
PURPOSE: To evaluate the safety and efficacy of alteplase (TPA) for restoring function to occluded central venous catheters (CVCs). PATIENTS AND METHODS: The study design was a phase III, open-label, ...
Although beneficial within 4.5 hours of stroke onset, administering recombinant tissue plasminogen activator (tPA) beyond that window appears to increase the risk of dying, a pooled analysis of eight ...
The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...
Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase. Bolus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback